| Literature DB >> 28164733 |
Ye Feng1, Yan Tang1, Hongwei Zhou1, Kaiqing Xie1.
Abstract
BACKGROUND: The level of interleukin-6 (IL-6) and its gene polymorphism are associated with the end-stage renal disease (ESRD) and the related complications. This study aimed to investigate the correction between IL-6 -174G/C polymorphism and ESRD by meta-analysis.Entities:
Keywords: Interleukin-6; correlation; end-stage renal disease; meta-analysis; polymorphism
Mesh:
Substances:
Year: 2017 PMID: 28164733 PMCID: PMC6014497 DOI: 10.1080/0886022X.2017.1281146
Source DB: PubMed Journal: Ren Fail ISSN: 0886-022X Impact factor: 2.606
Figure 1.Flowchart on the selection of the literatures.
Basic characteristics and quality of included literatures on correlation between IL-6 -174G/C polymorphism and ESRD.
| First author | Year | Race | Country | Case group | Control group | HWE (P) | NOS scores | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GG | GC | CC | N | GG | GC | CC | N | ||||||
| Buckham | 2010 | Caucasian | Blended countries | 217 | 299 | 107 | 623 | 194 | 258 | 90 | 542 | 0.79 | 6 |
| Kandil | 2013 | African | Egypt | 54 | 14 | 2 | 70 | 21 | 8 | 1 | 30 | 0.83 | 7 |
| Losito | 2003 | Caucasian | UK | 94 | 57 | 10 | 161 | 105 | 58 | 6 | 169 | 0.56 | 7 |
| Ng | 2008 | Caucasian | USA | 83 | 45 | 24 | 152 | 72 | 74 | 22 | 168 | 0.66 | 7 |
| Ranganath | 2009 | Asian | India | 162 | 80 | 16 | 258 | 515 | 53 | 1 | 569 | 0.76 | 6 |
IL-6: interleukin-6; ESRD: end-stage renal disease; HWE: Hardy–Weinberg equilibrium; NOS: Newcastle Ottawa scale.
Meta-analysis of literatures on correlation between IL-6 -174G/C polymorphism and ESRD in Caucasians.
| Subgroup | Genotype comparison | Heterogeneity test | Statistical model | Combined effect | |||
|---|---|---|---|---|---|---|---|
| I2(%) | OR | 95%CI | |||||
| Total | C versus G | 95 | <.01 | REM | 1.36 | 0.69–2.66 | .38 |
| CC + GC versus GG | 95 | <.01 | REM | 1.28 | 0.58–2.82 | .54 | |
| CC versus GG + GC | 70 | .01 | REM | 1.71 | 0.82–3.54 | .15 | |
| CC versus GG | 75 | <.01 | REM | 1.74 | 0.76–3.99 | .19 | |
| GC versus GG | 94 | <.01 | REM | 1.18 | 0.55–2.54 | .67 | |
| Caucasians | C versus G | 22 | .28 | FEM | 1.01 | 0.88–1.16 | .86 |
| CC + GC versus GG | 59 | .09 | REM | 0.93 | 0.67–1.30 | .68 | |
| CC versus GG + GC | 0 | .57 | FEM | 1.12 | 0.86–1.46 | .42 | |
| CC versus GG | 0 | .55 | FEM | 1.09 | 0.81–1.45 | .58 | |
| GC versus GG | 69 | .04 | REM | 0.87 | 0.58–1.30 | .50 | |
ESRD: end-stage renal disease; OR: odds ratio; 95%CI: 95% confidence interval; REM: randomized effects model; FEM: fixed effects model.
Figure 2.Meta-analysis on correlation between allele (C versus G) and ESRD.
Figure 3.Meta-analysis on correlation between dominant model (CC + CG versus GG) and ESRD.
Figure 4.Meta-analysis on correlation between recessive model (CC versus GG + CG) and ESRD.
Figure 5.Meta-analysis on correlation between homozygous model (CC versus GG) and ESRD.
Figure 6.Meta-analysis on correlation between heterozygous model (CG versus GG) and ESRD.
Figure 7.Funnel plot of IL-6 -174G/C polymorphism.